Alzheimer’s Blood Tests Are Changing Early Detection: What the Latest Research Means for Families

For decades, one of the greatest challenges in Alzheimer’s disease has been that by the time memory problems become obvious, changes in the brain may have been developing for many years.

That is beginning to change.

One of the most promising areas of Alzheimer’s research is not a new medication. It is something much simpler:

A blood test.

Researchers have made remarkable progress in detecting biological signs associated with Alzheimer’s disease through blood biomarkers, particularly a protein called phosphorylated tau 217, or p-tau217.

Recent research presented in 2026 has pushed the science another step forward. Instead of asking only whether a blood test can help identify Alzheimer’s disease, researchers are beginning to ask whether these biomarkers can help predict who may develop cognitive impairment years before symptoms become obvious.

For millions of families affected by Alzheimer’s disease, that could eventually change when and how the disease is diagnosed, treated and perhaps even prevented.

Why Is Early Detection of Alzheimer’s Disease So Important?

Alzheimer’s disease does not suddenly begin when someone forgets a name, repeats a question or becomes confused.

The biological process can begin many years earlier.

Two of the best-known changes associated with Alzheimer’s are the accumulation of amyloid-beta plaques and abnormal tau proteins in the brain.

Historically, determining whether these changes were present could require specialized testing such as a PET scan or analysis of cerebrospinal fluid obtained through a lumbar puncture.

These methods can be extremely useful, but they are more expensive, invasive or difficult to make widely available than an ordinary blood draw.

That is why blood biomarkers have generated so much excitement.

Imagine going to a physician for a blood test that helps determine whether Alzheimer’s-related biological changes are occurring in the brain.

That possibility is moving much closer to everyday medicine.

What Is p-tau217?

P-tau217 is a particular form of the tau protein that can be measured in blood.

Research has found that elevated levels of p-tau217 are strongly associated with the biological changes seen in Alzheimer’s disease.

This makes it potentially valuable for helping physicians determine whether cognitive problems may be related to Alzheimer’s rather than another cause.

But the research is moving beyond diagnosis.

Scientists are investigating whether p-tau217 can help identify people who appear cognitively normal today but have a significantly greater likelihood of developing cognitive impairment later.

That is where some of the newest findings become especially interesting.

What Did Researchers Report in 2026?

Research presented at the 2026 Alzheimer’s Association International Conference (AAIC) provided additional evidence that p-tau217 could become an important tool for predicting future Alzheimer’s-related cognitive decline.

One reported study followed cognitively healthy older adults and examined their blood p-tau217 levels along with amyloid PET imaging.

Among participants with very high p-tau217 levels and elevated amyloid detected by PET imaging, approximately 78% developed cognitive impairment within 10 years.

Roughly one-third developed impairment within approximately five years.

That does not mean a high p-tau217 result guarantees that someone will develop dementia.

It does mean researchers are getting better at identifying biological risk long before the symptoms traditionally associated with Alzheimer’s become obvious.

That distinction is extremely important.

Can a Blood Test Diagnose Alzheimer’s Disease?

Blood tests are increasingly becoming part of the diagnostic process, but families should understand what they can and cannot currently tell us.

In 2025, the U.S. Food and Drug Administration cleared the first blood test intended to aid in diagnosing Alzheimer’s disease: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio.

The test measures proteins associated with Alzheimer’s pathology and can help physicians determine whether amyloid plaques are likely to be present.

But the FDA specifically cautions that the test is not intended to be used as a stand-alone screening or diagnostic test.

A physician still needs to consider the entire clinical picture.

That can include cognitive testing, medical history, medications, neurological examination and, when appropriate, additional biomarker or imaging studies.

In other words:

A blood test can provide powerful information, but it does not replace a physician’s evaluation.

Why This Could Change Alzheimer’s Treatment

Early detection becomes increasingly valuable because Alzheimer's treatment itself is changing.

For many years, available medications primarily treated symptoms.

Today, disease-modifying treatments such as lecanemab (Leqembi) and donanemab (Kisunla) target amyloid in the brain and have demonstrated an ability to slow cognitive and functional decline in appropriately selected people with early Alzheimer’s disease.

These drugs are not cures.

They also carry potentially serious risks and are not appropriate for everyone.

But they have introduced an entirely different question:

If treatment works best early, how do we identify Alzheimer's as early as possible?

Blood biomarkers may eventually become an important part of that answer.

Instead of waiting until significant memory loss occurs, physicians could potentially identify biological Alzheimer’s much earlier and determine whether additional testing or treatment should be considered.

The Bigger Goal: Finding Alzheimer’s Before Dementia

Perhaps the most exciting implication of blood biomarker research goes beyond diagnosing people who already have symptoms.

Researchers ultimately want to identify Alzheimer’s disease during its preclinical stage.

That means biological changes are occurring, but the person is still functioning normally.

Think about how medicine approaches cholesterol.

Doctors do not wait for someone to have a heart attack before measuring cardiovascular risk.

They measure cholesterol, blood pressure and other risk factors years earlier and intervene when appropriate.

Alzheimer’s researchers are working toward a similar model.

The long-term objective could become:

Identify risk. Confirm biological changes. Intervene early. Delay or prevent cognitive decline.

We are not yet at the point where medicine can guarantee that outcome.

But the science is moving closer to making that strategy possible.

Could Alzheimer’s Eventually Be Prevented?

This is one of the biggest questions researchers are now attempting to answer.

If Alzheimer's-related brain changes can be detected 10, 15 or perhaps even 20 years before dementia develops, researchers gain an enormous window in which to intervene.

Future prevention strategies could potentially combine several approaches, including:

• Disease-modifying medications

• Cardiovascular risk management

• Regular physical activity

• Blood-pressure management

• Diabetes management

• Healthy nutrition

• Cognitive stimulation

• Social engagement

• Better sleep

• Hearing-loss treatment

No single lifestyle change has been proven to prevent every case of Alzheimer’s.

However, growing evidence suggests that brain health is connected to overall health and that addressing multiple modifiable risk factors may help reduce dementia risk.

The combination of biomarker testing and prevention research could therefore become one of the most important directions in Alzheimer's science.

Why Researchers Are Looking Beyond Amyloid

Another important development is that scientists increasingly recognize that Alzheimer’s is more complicated than one abnormal protein.

Amyloid is important.

Tau is important.

But researchers are also investigating inflammation, immune-system responses, vascular health, metabolism, synaptic function and other biological mechanisms.

The 2026 Alzheimer’s drug-development pipeline contains approximately 158 candidate therapies across 192 clinical trials, with dozens reaching late-stage clinical testing.

That diversity matters.

The future of Alzheimer's treatment may ultimately resemble treatment for diseases such as cancer, where different medications attack different parts of the disease process.

A person might eventually receive one treatment targeting amyloid, another targeting tau or inflammation, along with aggressive management of cardiovascular and lifestyle risk factors.

Blood biomarkers could help physicians determine which biological processes are occurring and when intervention should begin.

What Does This Mean for Families Today?

It is important to separate exciting research from what people should actually do right now.

A person without memory problems should not assume that everyone needs an Alzheimer's blood test.

Similarly, people should not attempt to interpret biomarker results without medical guidance.

However, if someone is experiencing persistent memory or cognitive changes, earlier evaluation is increasingly important.

There are many potential causes of memory problems, some of which may be treatable.

Vitamin deficiencies, thyroid problems, medication side effects, depression, sleep disorders and other medical conditions can sometimes produce symptoms that resemble dementia.

A proper medical evaluation helps determine what may actually be happening.

And if Alzheimer's disease is suspected, physicians now have more diagnostic tools available than they did only a few years ago.

Frequently Asked Questions

Is there really a blood test for Alzheimer’s disease?

Yes. Blood tests measuring Alzheimer's-related biomarkers are now available, and the FDA cleared the first blood test designed to aid in diagnosing Alzheimer's disease in 2025. These tests should be interpreted by qualified medical professionals and are not intended to function as simple stand-alone screening tests.

What is p-tau217?

P-tau217 is a form of phosphorylated tau protein found in blood. Elevated levels are strongly associated with biological changes related to Alzheimer's disease and are being studied for both diagnosis and prediction of future cognitive decline.

Can p-tau217 predict whether I will get Alzheimer’s?

It can help estimate biological risk, but it cannot tell an individual with certainty that he or she will develop Alzheimer's dementia. Research suggests elevated p-tau217 combined with other biomarkers can identify groups at substantially higher risk of future cognitive impairment.

Can Alzheimer’s be detected before memory loss begins?

Increasingly, yes. Amyloid PET scans, cerebrospinal-fluid testing and emerging blood biomarkers can detect biological changes associated with Alzheimer's before dementia becomes clinically apparent.

Is there a cure for Alzheimer’s disease?

No. There is currently no cure for Alzheimer's disease. However, disease-modifying medications can modestly slow progression in certain people with early Alzheimer's, and many additional treatments are under investigation.

A Remarkable Change in the Alzheimer’s Conversation

For families who have watched someone they love live with Alzheimer's disease, scientific progress can sometimes feel painfully slow.

There is still an enormous amount researchers do not know.

There is still no cure.

And today's treatments cannot restore memories that Alzheimer's has already taken away.

But something fundamental has changed.

Ten years ago, much of the conversation centered on managing symptoms after dementia appeared.

Today researchers are increasingly discussing:

Detecting Alzheimer's before dementia.

Predicting who is most at risk.

Treating the biological disease earlier.

Slowing its progression.

And ultimately:

Preventing cognitive decline before it begins.

The development of Alzheimer's blood biomarkers such as p-tau217 may prove to be one of the technologies that makes that transition possible.

For families affected by this devastating disease, that represents something worth following closely.

---

A Cause Close to Our Hearts

At Your Home Sold Guaranteed Realty Advisors LLC, Alzheimer's awareness is more than something we occasionally write about.

We believe in supporting families, caregivers and researchers working toward a future in which fewer families have to experience the devastating effects of this disease.

We will continue sharing meaningful Alzheimer's research developments as scientists work toward earlier detection, better treatment and, ultimately, prevention.

Go Serve Big®.

Sources & Further Reading

• Alzheimer’s Association International Conference (AAIC), 2026 research announcements

• U.S. Food and Drug Administration, Alzheimer’s disease blood-test clearance

• Alzheimer’s Association, blood biomarker and early-detection research

• Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2026 Alzheimer’s disease drug-development pipeline